|
Tabla 1: Prevalencia de carbapenemasas en niños.* |
|||||||
|
Gen |
Autor (año) |
||||||
|
Gajic I (2021) N = 13 |
Bello-López (2020) N = 24 |
Mancilla- Rojano (2020) N = 48 |
Lukic-Grlic (2020) N = 12 |
Hao-Yuan (2018) N = 3 |
Yili Chen (2018) N = 86 |
Karaaslan A (2016) N = 55 |
|
|
blaOXA-23 |
0 |
100 |
51.13 |
75 |
0 |
90.7 |
31 |
|
blaOXA-24 |
100 |
0 |
4.54 |
25 |
0 |
23.3 |
2 |
|
blaOXA-58 |
0 |
0 |
2.27 |
0 |
0 |
23.3 |
11 |
|
blaOXA-66** |
100 |
ND |
ND |
ND |
ND |
ND |
ND |
|
blaOXA-72*** |
100 |
ND |
ND |
ND |
ND |
ND |
ND |
|
blaOXA-80** |
ND |
ND |
ND |
ND |
100 |
ND |
ND |
|
blaIMP |
ND |
0 |
ND |
0 |
0 |
0 |
0 |
|
blaSPM |
ND |
0 |
ND |
0 |
0 |
0 |
ND |
|
blaVIM |
ND |
0 |
ND |
0 |
0 |
0 |
ND |
|
blaNDM |
ND |
0 |
ND |
0 |
0 |
23.3 |
22 |
|
blaIMI |
ND |
0 |
ND |
0 |
0 |
0 |
0 |
|
blaKPC |
ND |
0 |
ND |
0 |
0 |
0 |
0 |
|
blaOXA-23 + blaOXA-24 |
ND |
ND |
ND |
ND |
ND |
ND |
2 |
|
blaOXA-58 + blaMP-1 |
ND |
ND |
ND |
ND |
ND |
ND |
7 |
|
blaOXA-24 + blaNDM |
ND |
ND |
ND |
ND |
ND |
ND |
6 |
|
blaOXA-58 + blaNDM |
ND |
ND |
ND |
ND |
ND |
ND |
3 |
|
blaOXA-23 + blaIMP-1 |
ND |
ND |
ND |
ND |
ND |
ND |
2 |
|
blaOXA-58 + blaOXA-24 + blaIMP-1 |
ND |
ND |
ND |
ND |
ND |
ND |
3 |
|
* Prevalencia expresada en porcentaje. ** Pertenece al grupo de blaOXA-51. *** Pertenece al grupo de blaOXA-24. ND = no disponible. |
|||||||